RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL

Leukemia

Volumn 12, Issue 9, 1998, Pages 1349-1354

  Tobal, K ^a   Liu Yin, J A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

APL; Minimal residual disease; PML RARA; RT PCR; t(15; 17)

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CLINICAL ARTICLE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031708687     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401133     Document Type: Article

References (23)

1. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 8010: 549-550.
2. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 1990; 347: 558-561.
3. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
4. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, Dube I, Winfield DA, Kingston J, Hagemeijer A, Rees JKH, Lister TA, Solomon E. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992; 82: 529-540.
5. Grignani F, Fagioli M, Ferrucci PF, Alcalay M, Pelicci PG. The molecular genetics of acute promyelocytic leukemia. Blood Rev 1993; 7: 87-93.
6. Tobal K, Saunders MJ, Grey MR, Liu Yin JA. Persistence of RARαPML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol 1995; 90: 615-618.
7. LoCoco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Patti MC, Meloni G, Mandelli F, Grignani F, Masera G, Barbui F, Pelicci PG. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992; 340: 1437-1438.
8. Huang W, Sun G-L, Li X-S, Cao Q, Lu Y, Jang G-S, Zhang F-Q, Chai J-R, Wang Z-Y, Waxman S, Chen Z, Chen S-J. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase. Blood 1993; 82: 1264-1269.
9. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell JR. Detection of minimal residual disease in acute promyelocytic leukemia by reverse transcriptase polymerase chain reaction assay for PML-RARα fusion mRNA. Blood 1993; 82: 16891694.
10. Ikeda K, Sasaki K, Tasaka T, Nagai M, Kawanishi K, Takahara J, Irino S. Reverse transcription-polymerase chain reaction for PMLRAR alpha fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection. Leukemia 1993; 7: 544-548.
11. Laczika K, Mitterbauer G, Korninger L, Knobl P, Achwarzinger I, Kapiotis S, Haas OA, Kyrle PA, Pont J, Oehler L et al. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)negativity by combined treatment with all-frans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia 1994; 8: 1-5.
12. Seale J, Marcus R, Janossy G, Swirsky D, Goldman J, Cross N, Pandolfi PP. Quantitative assessment of minimal residual disease in acute promyelocytic leukemia by RT-PCR: evaluation of techniques to improve sensitivity. Blood 1994; 84 (Suppl. 1): 301 a.
13. Devaraj PE, Foroni L, Prentice GH, Hoffbrand VA, Seeker-Walker LM. Relapse of acute promyelocytic leukemia follows serial negative RT-PCR assays: a cautionary tale. Leukemia Res 1996; 20: 733-737.
14. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Patti MC, Mandelli F, Pelicci PG, Lo Coco F. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993; 82: 3556-3559.
15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gallon DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of the acute myeloid leukemia. Ann Intern Med 1985; 103: 620-625.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
17. Lanotte M, Martin-Thouvenin V, Najman S, Ballerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 75: 1080-1086.
18. Lo Coco F, Diverio D, Awisati G, Luciano A, DeSantis S, Santoro A, Pane F, Martinelli G, Pelicci PG, Vegna MI, Saglio G, Biondi A, Mandelli F. Prospective RT-PCR monitoring of minimal residual disease in acute promyelocytic leukeima (APL) patients enrolled in the multicentric GIMEMA-AIEOP 'AIDA' trial. Blood 1997; 90 (Suppl 1): a1734.
19. Seale JRC, Varma S, Swirsky DM, Pandolfi PP, Goldman JM, Cross NCP. Quantification of PML-RARα transcripts in acute promyelocytic leukaemia: explanation of the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon. Br J Haematol 1996; 95: 95-101.
20. Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F, Lo Coco F. Improved rapid detection of the PML/RARα fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214-1216.
21. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82: 712-715.
22. Saunders MJ, Tobal K, Liu Yin JA. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. Leukemia Res 1994; 18: 891-895.
23. Tobal K, Liu Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21). Bhod 1996; 88: 3704-3709.